Business Wire

CA-PSMF

12.1.2021 14:02:34 CET | Business Wire | Press release

Share
Dr. Mike Durkin Assumes Role as Vice Chairman of Patient Safety Movement Foundation Board of Directors

The Patient Safety Movement Foundation (PSMF) , a global non-profit on a mission to achieve zero preventable patient deaths by 2030, has appointed Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc to serve as vice chairman of the board of directors. Dr. Durkin will work alongside Chairman Michael A.E. Ramsay, MD, FRCA to provide guidance and strategic support of the organization’s goal to create safer and more reliable healthcare systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005212/en/

“Dr. Durkin has been an invaluable member of the Patient Safety Movement Foundation board since he joined in 2018, and we are pleased he has accepted this leadership role,” said Dr. Ramsay. “His experience leading the National Patient Safety Improvement Programme for the National Health Service (NHS) England and work with the World Health Organization’s international development of patient safety systems make him an ideal fit to help lead our organization as we continue to grow globally.”

Durkin brings 30 years of experience in medical management and leadership to his role with PSMF. He currently maintains positions as the visiting professor and senior advisor on patient safety policy and leadership of the NIHR Patient Safety Translational Research Centre at the Institute of Global Health Innovation at Imperial College London and as associate non-executive director at NHS Resolution. From 2012 to 2017, he served as the national director of patient safety for England’s NHS. Prior to these roles, he held attending, research and teaching positions in cardiovascular anesthesia and critical care at London, Yale and Bristol universities. He served as executive medical director at Gloucestershire Royal Hospital and held successive executive medical director positions for England’s strategic health authorities culminating as the medical director of the NHS for the South of England supporting a population of 16 million people, prior to becoming the national director in 2012. His passion for patient safety led him to assemble the Berwick Advisory Board in 2013 to advise on creating conditions to improve the safety of patients in England. In 2015, he was commissioned by the secretary of state for health to chair an expert advisory group that led to the establishment of the Healthcare Safety Investigation branch. He also headed the development of the Ministerial Inter-Governmental Summits on Patient Safety held in the UK (2016), Germany (2017), Japan (2018) and Saudi Arabia (2019).

“I am honored to be appointed as vice chairman of the board of directors of the Patient Safety Movement Foundation,” states Durkin. “With the recent launch of our new commitment model and amid a global pandemic, I believe the healthcare industry across the globe is ready and prepared for change and I look forward to working alongside the leadership team to further our shared mission.”

Durkin was appointed officer of the Order of the British Empire (OBE) by Her Majesty The Queen for his services to patient safety and in 2018 was selected as an inaugural member of the International Academy of Safety and Quality. Durkin holds an honorary doctorate from the University of the West of England and he was awarded the highest accolade of the Royal College of Physicians of London for service to patient safety, their Honorary Fellowship in 2017. He is chair of the management board of NICE National Clinical Guideline Centre and sits on multiple national and international research, policy and patient safety advisory boards.

To learn more about the Patient Safety Movement Foundation and its leadership team, visit: https://patientsafetymovement.org/about/

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit on a mission to eliminate preventable deaths from hospital errors. PSMF uniquely brings patients and patient advocates, healthcare providers, medical technology companies, government, employers and private payers together under the same cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org to learn more, and follow PSMF on Linkedin , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release

The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,

Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release

Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti

Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa

Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release

Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96

SES Announces Results of the Extraordinary General Meeting of Shareholders17.6.2026 19:23:00 CEST | Press release

SES (the “Company”) held an Extraordinary General Meeting (“EGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions. In particular, shareholders approved the cancellation of shares repurchased under the Company’s share buyback program of 2 November 2023, as amended on 2 May 2024, resulting in a corresponding reduction of the Company’s share capital. Shareholders also approved amendments to the Company’s articles of association, including indemnification for Board members and executives, as well as updates relating to the conduct of shareholder meetings. Detailed results on all matters voted on at the EGM will be available on the company’s webpage: https://www.ses.com/company/investors/shareholder-information/general-meeting-shareholders Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye